LCAP vs. LPCN, RPID, XAIR, CLNN, EQ, BIVI, AXDX, BOLT, ENLV, and ICU
Should you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Lipocine (LPCN), Rapid Micro Biosystems (RPID), Beyond Air (XAIR), Clene (CLNN), Equillium (EQ), BioVie (BIVI), Accelerate Diagnostics (AXDX), Bolt Biotherapeutics (BOLT), Enlivex Therapeutics (ENLV), and SeaStar Medical (ICU). These companies are all part of the "medical" sector.
Lipocine (NASDAQ:LPCN) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Lionheart Acquisition Co. II has lower revenue, but higher earnings than Lipocine.
9.1% of Lipocine shares are held by institutional investors. 6.1% of Lipocine shares are held by company insiders. Comparatively, 19.4% of Lionheart Acquisition Co. II shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Lionheart Acquisition Co. II's return on equity of -37.62% beat Lipocine's return on equity.
Lipocine received 343 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users.
Lipocine has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Lionheart Acquisition Co. II has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
In the previous week, Lipocine had 1 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Lionheart Acquisition Co. II. Lionheart Acquisition Co. II's average media sentiment score of 0.47 beat Lipocine's score of 0.00 indicating that Lipocine is being referred to more favorably in the media.
Summary
Lipocine beats Lionheart Acquisition Co. II on 7 of the 10 factors compared between the two stocks.
Get Lionheart Acquisition Co. II News Delivered to You Automatically
Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lionheart Acquisition Co. II Competitors List
Related Companies and Tools
